Executive Summary

Valued at 1.8 USD Billion in 2025, the AI Medical Diagnostics Market is forecast to reach 28.2 USD Billion by 2035, expanding at a CAGR of 31.88%. This trajectory covers the ten-year window from 2025 through 2035, with the market reaching 2.33 USD Billion in 2026 as adoption moves past early pilots into reimbursed clinical workflows.

Growth is anchored in regulatory clearance and reimbursement coding rather than experimentation. The FDA has cleared 129 radiology AI devices since 2015, and new CMS codes now reimburse stroke, cardiac CTA and breast-cancer AI triage, converting pilot deployments into billable clinical services across US hospital networks.

North America held 53.48% of the market in 2025, supported by its FDA clearance volume and CMS coding structure, while Asia-Pacific is the fastest-growing region as government-backed EMR rollouts and open-access datasets such as IndiaAI expand domestic algorithm development. Diagnostic Imaging leads diagnostic modality demand with a 57.64% share.

EU MDR classification of diagnostic algorithms as high-risk under the AI Act adds conformity-assessment cost that slows deployment timelines in Europe. The competitive landscape remains moderately consolidated, with imaging incumbents and specialist AI vendors competing on regulatory clearance breadth and reimbursement coding rather than price.

Key Takeaways

• The AI Medical Diagnostics Market is valued at USD 2.33 Billion in 2026, projected to reach USD 28.192 Billion by 2035 at a 31.88% CAGR.
• Diagnostic Imaging leads By Diagnostic Modality with a 57.64% share, ahead of In Vitro Diagnostics.
• In Vitro Diagnostics is the fastest-growing modality, expanding at a 32.9% CAGR to 2035.
• North America held 53.48% of the market in 2025, the largest regional base.
• FDA clearance of 129 radiology AI devices since 2015 has anchored deployment across hospital and imaging workflows.
• EU MDR/AI Act classification of diagnostic imaging algorithms as high-risk adds compliance cost to European rollout.

Market Definition and Scope

The AI Medical Diagnostics Market comprises software, algorithms, and integrated systems that apply machine learning to interpret in vitro diagnostic assays, diagnostic imaging studies, digital pathology slides, and adjunct modalities including genomics, ECG, ophthalmology, and dermatology data. Boundary includes standalone software as a medical device, imaging-platform-embedded algorithms, and cloud-based analysis services sold to hospitals, diagnostic laboratories, ambulatory surgical centers, and research or specialty-clinic end users, supporting indications spanning oncology, cardiology, neurology, infectious disease, obstetrics and gynecology, and respiratory care, valued at USD 2.33 Billion in 2026.

Excluded are non-AI diagnostic hardware sold without algorithmic interpretation, hospital EHR and practice-management platforms lacking a diagnostic output, AI tools applied to drug discovery or clinical-trial recruitment rather than patient-level diagnosis, and general wellness or fitness-tracking applications that carry no defined indication or coverage decision.

Market Trends

Medicare Coding Is Turning AI-Enabled Reads Into a Billed Service Line

CMS is converting AI diagnostics from pilot software into billed clinical service. In the CY2026 Medicare Physician Fee Schedule, the payment rate for HeartFlow’s FFRCT Analysis rises from USD 997 to USD 1,017, CMS set roughly USD 950 for AI-enabled coronary plaque assessment, and hospital outpatient CCTA payment rose from USD 175 to USD 357 in January 2025. CMS is also drafting a “Software as a Medical Service” payment pathway for the CY2027 OPPS/ASC rule, with comments due 31 August 2026. Cardiology and imaging groups billing under these codes gain a repeatable revenue base, pulling AI diagnostics from research budgets into recurring per-scan demand through 2035.

Radiology Absorbs Three-Quarters of New FDA AI Device Authorisations

Regulatory clearance activity keeps concentrating in imaging rather than spreading across specialties. Of 1,451 AI-enabled devices the FDA had authorised through end-December 2025, 1,104 – 76% – were radiology devices, with radiology taking 75% of 2025 authorisations alone. GE HealthCare leads the list with 120 cumulative authorisations, built partly through acquisitions of Caption Health, MIM Software and Bay Labs, and has set a target of more than 200 by 2028. Imaging centres and OEM platform vendors capture the resulting volume; capital and channel partnerships keep clustering around radiology workflows, reinforcing imaging AI as the largest single demand pool through the 2025-2035 forecast period.

EHR Vendors Are Displacing Third-Party Tools as the Default AI Channel Into Hospitals

Hospitals are standardising on EHR-embedded predictive AI rather than best-of-breed third-party software. National adoption reached 71% of US hospitals in 2024, up from 66% in 2023, and 80% of adopters sourced their model from their EHR developer versus 52% using third-party developers; hospitals on the market-leading EHR vendor used predictive AI at 90%, against 50% for all other vendors combined. Facilities above 400 beds adopted fastest, at 96%. As EHR platforms bundle diagnostic AI into existing contracts, purchasing shifts from standalone software deals toward platform attach, supporting the market’s climb from USD 2.33 Billion in 2026 toward USD 28.192 Billion by 2035 at a 31.88% CAGR.

Growth Drivers and Restraints

Medicare coding converts AI-assisted reads into a billable procedure

CMS reimbursement codes are turning FFRCT and coronary AI outputs into paid line items, not free clinical add-ons. HeartFlow’s FFRCT Analysis has assessed coronary artery disease in more than 400,000 patients cumulatively, including 132,000 in 2024, generating USD 125.8 Million in 2024 revenue, up 44% year on year, under an existing CPT billing code. CMS’s CY2026 Physician Fee Schedule raises the FFRCT payment rate from USD 997 to USD 1,017 and sets roughly USD 950 for AI-enabled coronary plaque assessment, while CCTA hospital outpatient payment rose from USD 175 to USD 357 effective January 2025. Cardiovascular imaging absorbs the effect first, since it holds the deepest existing CPT/HCPCS code set.

European HTA pathways are formalizing reimbursed deployment

NICE’s TA943 recommends hybrid closed loop insulin delivery systems for all children under 18 with type 1 diabetes and for adults meeting HbA1c or hypoglycaemia thresholds, backed by a phased five-year NHS England and NHS Wales rollout that began in early 2024, following guidance published 19 December 2023. The EU AI Act separately classifies diagnostic imaging algorithms as high-risk systems, overlaying the Medical Device Regulation and In Vitro Diagnostic Regulation while offering regulatory sandboxes and harmonized conformity assessment. Together the two frameworks convert clinical validation into a funded coverage route across Europe’s largest single-payer systems, shifting adoption toward guideline-anchored, budgeted procurement in diabetes management and imaging.

OEM acquisitions are bundling AI directly into imaging hardware

GE HealthCare agreed in July 2024 to acquire Intelligent Ultrasound Group plc’s clinical AI software business, including ScanNav Assist and SonoLyst, for approximately USD 51 Million, funded from cash on hand and expected to close in the fourth quarter of 2024. The deal folds point-of-care image-guidance algorithms into an incumbent ultrasound platform rather than leaving them as standalone software sales. In the Middle East, Saudi Arabia’s MDS-G53 guidance sets Medical Device Marketing Authorisation requirements specific to AI and big-data-based devices, requiring accuracy demonstration for the claimed diagnostic indication and giving OEMs a defined approval route for bundled hardware-software launches outside the US and Europe.

Clinical evidence has not kept pace with regulatory clearance

Of 1,357 FDA-cleared or approved AI/ML-enabled medical devices analysed through 5 December 2025, only 34 (2.5%) had a registered prospective trial and just 3 (0.2%) were evaluated against patient-centred outcomes such as mortality, morbidity or readmission; 62% of supporting studies relied on observational designs with small, homogeneous cohorts. Payers and guideline committees withhold coverage decisions until outcomes data exist, so the gap falls hardest on standalone diagnostic-support software without an established procedure code. Coding lags in parallel: of 26 CPT codes covering clinical AI solutions as of January 2026, only three hold permanent Category I status, leaving most reimbursement provisional.

Local validation burden and alert override slow institutional scaling

Hospitals must independently test each model before trusting it, and many lack the capacity to do so: in 2024, only 71% of US hospitals evaluated accuracy and 57% evaluated bias for all or most of their predictive AI models, and 15% and 21% respectively answered “don’t know” on those evaluations. The burden compounds an existing divide – predictive AI use ran 56% at rural hospitals versus 81% at urban hospitals, and 37% at independent hospitals versus 86% at multi-system members, in 2023-2024. Once deployed, rule-based alerting meets clinician resistance: a review of 8 studies covering 43,413 patients found drug-interaction alerts produced no significant mortality reduction, and physicians override more than 90% of alerts as clinically unproven.

Segment Analysis

By Diagnostic Modality

• In Vitro Diagnostics (fastest-growing, 32.9% CAGR) – Tests performed on blood, urine, or tissue samples outside the body using lab instruments and reagents to detect diseases or biomarkers

• Molecular Diagnostics
• Immunoassays & Clinical Chemistry
• Point-of-Care Tests
• Diagnostic Imaging (largest, 57.64% share) – Technologies such as X-ray, CT, MRI, and ultrasound that generate visual representations of internal body structures to identify abnormalities

• MRI
• CT
• X-ray
• Ultrasound
• PET/SPECT & Others
• Digital Pathology – The digitization, management, and viewing of pathology slide images on computer screens to support tissue-based diagnosis and analysis

• Whole Slide Imaging (WSI) Scanners
• Digital Pathology Software

• Image Analysis Software
• Image Management Software
• Storage & Communication Systems
• Other Modalities – Diagnostic approaches such as genomic sequencing, point-of-care testing, and physiological monitoring used alongside imaging and lab-based methods to inform clinical decisions

• Genomics
• Electrocardiogram (ECG)
• Ophthalmology
• Dermatology

Diagnostic Imaging led the AI medical diagnostics market with a 57.64% share in 2025. Its position rests on an entrenched installed base of MRI, CT, X-ray, and ultrasound systems that already generate standardized image data AI models can process without added capital outlay. Radiology departments pair these algorithms with existing PACS infrastructure, and reimbursement codes for AI-assisted image interpretation lower the adoption barrier relative to newer modalities. In Vitro Diagnostics is expanding fastest, at a 32.9% CAGR. Point-of-care molecular assays are shifting infectious disease and oncology biomarker testing away from centralized labs, and AI-driven interpretation of immunoassay and clinical chemistry results is compressing turnaround time from specimen to actionable result.

By Application

• Oncology (fastest-growing, 33.2% CAGR) – AI-based image and data analysis tools that detect, classify, and stage tumors from radiology, pathology, and genomic data to support cancer diagnosis
• Breast Cancer

• Mammography-Based Detection
• Ultrasound-Based Detection
• MRI-Based Detection

• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Cancers
• Cardiology – AI diagnostic systems that interpret ECGs, echocardiograms, and cardiac imaging to identify arrhythmias, structural defects, and coronary disease

• Arrhythmia Detection
• Coronary Artery Disease Detection
• Heart Failure Detection
• Structural Heart Disease Detection
• Neurology (largest, 25.21% share) – AI tools that analyze brain MRI, CT, and EEG data to detect stroke, dementia, epilepsy, and other neurological conditions

• Stroke Detection
• Alzheimer’s Disease & Dementia Detection
• Epilepsy Detection
• Multiple Sclerosis Detection
• Infectious Disease – AI applications that interpret chest X-rays, lab assays, and pathogen data to identify infections such as tuberculosis, pneumonia, and sepsis

• Tuberculosis Detection
• Sepsis Detection
• Other Infectious Diseases
• Obstetrics & Gynecology – AI-assisted ultrasound and imaging analysis used to monitor fetal development, screen for congenital anomalies, and evaluate gynecological conditions

• Fetal Anomaly Detection
• Cervical Cancer Screening
• Ovarian Cancer Detection
• Breast Cancer Screening
• Respiratory & Pulmonology – AI diagnostic tools that examine chest imaging and pulmonary function data to identify conditions like COPD, asthma, and lung nodules

• Pneumonia Detection
• COPD Detection
• Pulmonary Nodule Detection

• CT-Based Detection
• X-Ray-Based Detection
• Tuberculosis Screening
• Other Applications – AI diagnostic tools applied to additional clinical areas such as dermatology, ophthalmology, nephrology, and musculoskeletal conditions not covered elsewhere

• Ophthalmology
• Dermatology
• Nephrology
• Gastroenterology

Neurology held the largest application share, at 25.21% in 2025. Stroke care anchors this position: large-vessel-occlusion detection tools are built into emergency triage protocols, and the prevalence of stroke and dementia across ageing populations sustains steady imaging volume for AI interpretation. Established teleneurology and stroke-network reimbursement pathways further reduce adoption friction for hospitals. Oncology is growing fastest, at a 33.2% CAGR. Breast, lung, and colorectal cancer screening programs are incorporating AI-assisted mammography and CT nodule detection to raise early-detection rates, while companion-diagnostic algorithms tied to precision oncology therapies are pulling pathology and genomic AI tools into routine cancer workup.

By End-User

• Hospitals (largest, 57.88% share) – Inpatient and outpatient care facilities that deploy AI diagnostic software integrated with imaging, laboratory, and EHR systems to support clinician decision-making across departments

• Public/Government Hospitals
• Private Hospitals
• Diagnostic Laboratories (fastest-growing, 32.85% CAGR) – Independent or hospital-affiliated facilities that process pathology, radiology, and molecular specimens, using AI tools to flag abnormalities and prioritize cases for specialist review

• Independent Diagnostic Laboratories
• Hospital-based Laboratories
• Reference Laboratories

• Ambulatory Surgical Centers – Outpatient facilities performing same-day surgical and diagnostic procedures that use AI-enabled imaging and screening tools to support pre-procedural evaluation and triage
• Other End-Users – Settings such as research institutes, academic medical centers, and specialty or home-testing providers that apply AI diagnostic tools outside conventional hospital and laboratory workflows

• Research & Academic Institutes
• Specialty Clinics
• Home Care Settings

Hospitals accounted for 57.88% of the market in 2025. Their scale gives them the capital budgets and integrated EHR, PACS, and laboratory information systems needed to deploy AI diagnostics across radiology, pathology, and cardiology departments at once, and IDN group-purchasing contracts extend a single vendor relationship across multiple facilities. Diagnostic Laboratories are growing fastest, at a 32.85% CAGR. Independent and reference labs are adopting whole-slide-imaging and AI-assisted case triage to manage rising molecular and digital pathology test volumes, letting a fixed pathologist headcount clear a larger caseload as specimen volume climbs.

Regional Analysis

North America Leads on FDA Clearance Volume and CMS Coding

North America accounted for 53.48% of the AI medical diagnostics market in 2025, worth USD 0.947 Billion and the largest of the five regions tracked. The US FDA has cleared 129 radiology AI devices since 2015, and new CMS reimbursement codes now support monetization of stroke, cardiac CTA and breast-cancer AI triage tools. Clearance volume paired with billable codes gives providers a direct route from pilot to paid deployment, a combination that has kept the region ahead of Europe and Asia-Pacific through the current forecast cycle.

Is the EU AI Act Slowing Adoption in Europe?

Europe ranks second among the five regions, trailing North America without closing the gap in the near term. The EU AI Act classifies diagnostic imaging algorithms as high-risk, a designation that would raise compliance cost on its own, but Brussels paired it with regulatory sandboxes and a harmonized conformity-assessment route. Germany and France are both using that route to move algorithms toward CE marking, which channels adoption through a defined pathway rather than blocking it outright.

Asia-Pacific Moves Fastest on the Back of Public Data Infrastructure

Asia-Pacific is set to expand faster than any other region tracked through 2035. Government-backed electronic medical record rollouts across India, Japan, South Korea and China are feeding open-access datasets, including India’s IndiaAI programme, giving domestic developers a training-data base that shortens the path from prototype to deployable diagnostic model. Demand here is forming around data availability as much as clinical need, a pattern distinct from the reimbursement-led lead held by North America.

Middle East and Africa: Gulf Programmes Build the Referral Base

UAE-based M42 and PureHealth are building national-scale diagnostic and reference-laboratory capacity, including PureHealth’s PureLab platform in Abu Dhabi, creating a data and referral base that AI diagnostics vendors can plug into. Regional uptake follows Gulf healthcare-infrastructure investment more closely than local device manufacturing, while WHO prequalification and donor-funded programmes shape deployment across the wider African market, particularly for imaging tools placed in public referral hospitals.

South America: Brazil’s ANVISA Pathway Sets the Regional Pace

Brazil’s ANVISA regulates software-as-a-medical-device approvals for much of the South American market, and its pathway serves as the reference point neighbouring health authorities tend to follow. Public-tender procurement dominates purchasing, concentrating diagnostic AI adoption among large public hospital networks rather than a broad private-pay base. Out-of-pocket exposure stays high outside those tenders, slowing diffusion beyond flagship urban systems such as São Paulo.

Country Growth Comparison

The United States has generated 129 FDA radiology-AI clearances since 2015, paired with new CMS reimbursement codes covering stroke, cardiac CTA and breast-cancer AI triage – a coverage pathway distinct from any other national market discussed here. Germany and France sit inside the EU AI Act framework, which classifies diagnostic-imaging algorithms as high-risk but offsets that burden with regulatory sandboxes and a harmonized conformity-assessment route, trading US-style clearance speed for structured, bloc-wide market access. India, Japan, South Korea and China are building adoption on a different foundation: government-backed EMR rollouts and open-access datasets such as IndiaAI are lowering the data-acquisition cost facing domestic algorithm developers, a structural advantage neither the reimbursement-anchored United States nor the EU AI Act markets share. For entrants prioritizing near-term monetization, the US reimbursement route offers the clearest path; for scale, Asia-Pacific’s data infrastructure lowers the barrier to entry.

Competitive Landscape

The AI medical diagnostics market is moderately consolidated, contested between incumbent imaging OEMs and pure-play algorithm vendors. Competition centers on breadth of FDA-cleared indications, regulatory approval status, and installed-base lock-in through hospital picture-archiving and interventional-imaging platforms – clinical evidence and label scope determine which vendors radiologists and IDNs adopt first. No market-share dataset supports a top-five concentration figure; the field is instead led by a group of established players: Siemens Healthineers, GE HealthCare, Philips Healthcare, Aidoc, Viz.ai, RapidAI, HeartFlow, Qure.ai, VUNO Inc., RadNet, iCAD, Roche, PathAI, Nanox Imaging LTD and Riverain Technologies.

Clearance velocity has driven recent positioning. Aidoc received FDA clearance in January 2026 for the first comprehensive foundation-model triage tool in imaging, consolidating 14 indications into one CT workflow for acute abdominal findings, then raised a USD 150 Million Series E in April 2026 led by Goldman Sachs Alternatives to scale that model across CT and X-ray. Qure.ai secured FDA 510(k) Class II clearance for qXR-Detect in February 2026, covering six chest-X-ray regions of interest under a Predetermined Change Control Plan, extending its radiology footprint. RapidAI added five FDA clearances in November 2025 spanning large-vessel-occlusion, midline-shift and aortic assessment, broadening its stroke and trauma triage suite. HeartFlow closed an upsized Nasdaq IPO in August 2025, raising approximately USD 364.2 Million to fund commercial scaling of its cardiovascular imaging analytics. Siemens Healthineers received FDA clearance in May 2026 for six Artis interventional systems built on its Optiq AI imaging chain, reinforcing its incumbent equipment position against pure-play entrants.

Strategic Outlook

The widest whitespace lies less in new FDA authorisations than in closing the deployment gap between large, system-affiliated hospitals and the rural, independent, small-bed facilities trailing on predictive-AI adoption. EHR-developer-bundled AI, already the leading procurement channel, is the likeliest route to reach these laggards, since it lowers integration cost against third-party or self-built alternatives. Realising it depends on add-on reimbursement codes extending from isolated devices into broader, permanent coverage.

By 2035, the market’s structure is expected to tilt from device-count expansion toward outcomes-linked coverage, as payers and hospital evaluators push clinical-evidence generation – currently prospective and patient-outcome trials for only a small minority of authorised devices – from a compliance afterthought to a gating requirement. Radiology’s dominance among authorised devices is likely to narrow as inpatient risk-prediction and other embedded, EHR-native applications capture a larger share of new deployment.

AI Medical Diagnostics Market Report Scope

Attribute	Detail
Market Size 2025	1.77 (USD Billion)
Market Size 2026	2.33 (USD Billion)
Market Size 2035	28.19 (USD Billion)
Compound Annual Growth Rate (CAGR)	31.88% (2026 to 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Segment Analysis and Trends
Base Year	2025
Market Forecast Period	2026 – 2035
Historical Data	2020 – 2025
Market Forecast Units	USD Billion
Key Companies Profiled	Siemens Healthineers (DE); GE HealthCare (US); Philips Healthcare (NL); Aidoc (IL); Nanox Imaging LTD (Zebra Medical Vision) (IL); Riverain Technologies (US); VUNO Inc. (KR); Viz.ai (US); RapidAI (US); HeartFlow (US); Qure.ai (IN); RadNet (US)
Segments Covered	By Diagnostic Modality, By Application, By End-User
Key Market Opportunities	Health systems that still lack a defined reimbursement pathway for AI-assisted diagnostics, particularly across the Middle East, Africa and Latin America, represent the largest unclaimed patient population.
Key Market Dynamics	Health technology assessment and national payer coverage decisions, not regulatory clearance alone, now determine which AI diagnostic tools clinicians can actually access and use.
Regions Covered	North America, Europe, Asia-Pacific, Middle East and Africa, South America

Market Insights

Frequently Asked Questions

Explore key insights into the AI Medical Diagnostics Market, including market size, growth outlook, regional trends, leading segments, growth drivers, key players, and regulatory requirements.

01 How big is the AI Medical Diagnostics Market?

The AI Medical Diagnostics Market was valued at USD 1.77 Billion in 2025. Growth continued into 2026, with the market reaching an estimated USD 2.33 Billion, driven by expanding FDA device authorizations and new CMS reimbursement codes for imaging-based AI triage tools.

02 What is the growth forecast for the AI Medical Diagnostics Market?

The AI Medical Diagnostics Market is projected to grow from USD 1.77 Billion in 2025 to USD 28.192 Billion by 2035, expanding at a CAGR of 31.88% across the 2025-2035 forecast period as diagnostic imaging and in-vitro diagnostics algorithms move from pilot deployment to reimbursed clinical use.

03 Which region holds the largest share of the AI Medical Diagnostics Market?

North America held 53.48% of the AI Medical Diagnostics Market in 2025. The region’s lead rests on regulatory depth and reimbursement infrastructure, including FDA clearances for radiology AI devices and CMS codes supporting stroke, cardiac CTA and breast-cancer AI triage.

04 Which region is growing fastest in the AI Medical Diagnostics Market?

Asia-Pacific is the fastest-growing region in the AI Medical Diagnostics Market through 2035. Government-backed electronic medical record rollouts and open-access datasets such as IndiaAI are accelerating domestic algorithm development across India, Japan, South Korea and China.

05 Which segment leads the AI Medical Diagnostics Market?

Diagnostic Imaging leads the AI Medical Diagnostics Market with a 57.64% share by diagnostic modality. The segment’s dominance reflects the depth of FDA-authorized radiology algorithms across MRI, CT, X-ray and ultrasound, which account for a major share of regulator-cleared AI diagnostic devices.

06 What is driving growth in the AI Medical Diagnostics Market?

Expanding regulatory clearance and reimbursement coverage are the leading drivers of the AI Medical Diagnostics Market. FDA authorizations for AI-enabled devices have grown alongside new CMS payment codes, while OEM acquisitions consolidate installed bases and accelerate commercial scale.

07 Who are the key players in the AI Medical Diagnostics Market?

Siemens Healthineers, GE HealthCare and Philips Healthcare anchor the AI Medical Diagnostics Market alongside pure-play vendors Aidoc, Viz.ai and RapidAI, cardiovascular imaging specialist HeartFlow, and India-based radiology AI provider Qure.ai.

08 What regulatory approvals are required in the AI Medical Diagnostics Market?

AI diagnostic devices sold in major markets require clearance through pathways such as FDA 510(k), PMA or De Novo, EU MDR conformity assessment, or PMDA approval in Japan. The FDA had authorized 1,451 AI-enabled medical devices through December 2025, of which 76% were radiology devices.